Assessment of PI3K/AKT/PTEN signaling pathway activity in colorectal cancer using quantum dot‑conjugated antibodies

Waniczek,Dariusz; Śnietura,Mirosław; Lorenc,Zbigniew; Nowakowska‑Zajdel,Ewa; Muc‑Wierzgoń,Małgorzata

doi:10.3892/ol.2017.7392

Assessment of PI3K/AKT/PTEN signaling pathway activity in colorectal cancer using quantum dot‑conjugated antibodies

Authors:
- Dariusz Waniczek
- Mirosław Śnietura
- Zbigniew Lorenc
- Ewa Nowakowska‑Zajdel
- Małgorzata Muc‑Wierzgoń
View Affiliations

Affiliations: SHS in Katowice, Department of Surgery Propedeutics, Chair of General, Colorectal and Trauma Surgery, Medical University of Silesia, 40‑055 Katowice, Poland, Tumor Pathology Department, Maria Sklodowska‑Curie Memoria Cancer Center and Institute of Oncology, Gliwice Branch, 41‑120 Gliwice, Poland, SHS in Katowice, Chair of General, Colorectal and Polytrauma Surgery, Medical University of Silesia, 40‑055 Katowice, Poland, Department of Nutrition Related Disease Prevention, School of Public Health in Bytom, Medical University of Silesia, 40‑055 Katowice, Poland, Department of Internal Medicine, School of Public Health in Bytom, Medical University of Silesia, 40‑055 Katowice, Poland
Published online on: November 10, 2017 https://doi.org/10.3892/ol.2017.7392
Pages: 1236-1240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In certain patients with advanced colorectal cancer, loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) activity is observed. PTEN is a major gatekeeper gene of the AKT serine/threonine kinase (AKT) signaling pathway responsible for the proliferative activity of cells. The assessment of AKT activity may be a prognostic factor or a predictor of response to the targeted therapies against particular signaling proteins. To precisely identify the cause and the place of the pathway deregulation, it is necessary to identify phosphorylation states and concentrations of several proteins located at different levels of the regulatory cascade. In the present study, we propose the simultaneous use of specific antibodies conjugated with different quantum dots to highlight the nature of AKT/PKB cascade deregulation in patients with colorectal cancer and the loss of PTEN expression in tumor tissue. Fifty patients with colorectal cancer of no specific location were enrolled in the study. The expression of the PTEN protein, and concentrations of phosphorylated/activated forms of 3‑Phosphoinositide‑dependent kinase 1 (PDK1) and AKT were assessed using quantum dot‑conjugated antibodies. In patients with a diminished or complete loss of the PTEN expression in the tumor tissue increased levels of activated/phosphorylated forms of PDK1 (Phospho‑PDK1‑Ser241) and AKT (Phospho‑AKT‑Thr308) proteins were found, which are responsible for the permanent activation of the phosphoinositide 3‑kinase/AKT/PTEN signaling pathway in certain cases of colorectal cancer.

View Figures

View References

1	Davies EJ, Marsh Durban V, Meniel V, Williams GT and Clarke AR: PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine. J Pathol. 233:27–38. 2014. View Article : Google Scholar : PubMed/NCBI
2	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
3	Leslie NR and Downes CP: PTEN function: How normal cells control it and tumour cells lose it. Biochem J. 382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
4	Waniczek D, Śnietura M, Młynarczyk-Liszka J, Pigłowski W, Kopeć A, Lange D, Rudzki M and Arendt J: PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol. 64:15–20. 2013. View Article : Google Scholar : PubMed/NCBI
5	Waniczek D, Snietura M, Kopec A, Scieglinska D, Piglowski W, Lorenc Z, Muc-Wierzgon M and Nowakowska-Zajdel E: A novel quantitative method of pten expression assessment in tumor tissue. J Biol Regul Homeost Agents. 30:79–90. 2016.PubMed/NCBI
6	Smith AM, Duan H, Mohs AM and Nie S: Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev. 60:1226–1240. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fang M, Peng CW, Pang DW and Li Y: Quantum dots for cancer research: Current status, remaining issues, and future perspectives. Cancer Biol Med. 9:151–163. 2012.PubMed/NCBI
8	Iga AM, Robertson JH, Winslet MC and Seifalian AM: Clinical potential of quantum dots. J Biomed Biotechnol. 10:760872007.
9	Molecular Probes Inc., . Separating the conjugated antibody from unconjugated antibodyQdot antibody conjugation kits. Molecular Probes, Inc., . pp. 7–8. 2008
10	Wang Y and Chen L: Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine. 7:385–402. 2011. View Article : Google Scholar : PubMed/NCBI
11	Liu SL, Wang ZG, Zhang ZL and Pang DW: Tracking single viruses infecting their host cells using quantum dots. Chem Soc Rev. 45:1211–1224. 2016. View Article : Google Scholar : PubMed/NCBI
12	Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland JA and Byers RJ: Quantum dots light up pathology. J Pathol. 216:275–285. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zhao J, Qiu X, Wang Z, Pan J, Chen J and Han J: Application of quantum dots as vectors in targeted survivin gene siRNA delivery. Onco Targets Ther. 3:303–309. 2013. View Article : Google Scholar
14	Bayascas JR, Leslie NR, Parsons R, Fleming S and Alessi DR: Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol. 15:1839–1846. 2005. View Article : Google Scholar : PubMed/NCBI
15	Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 8:1195–1198. 1998. View Article : Google Scholar : PubMed/NCBI
16	Bayascas JR: Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle. 7:2978–2982. 2008. View Article : Google Scholar : PubMed/NCBI
17	Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, et al: 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 69:6299–6306. 2009. View Article : Google Scholar : PubMed/NCBI
18	Yazdani Y, Farazmandfar T, Azadeh H and Zekavatian Z: The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci. 23:92016. View Article : Google Scholar : PubMed/NCBI
19	Colakoglu T, Yildirim S, Kayaselcuk F, Nursal TZ, Ezer A, Noyan T, Karakayali H and Haberal M: Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: Is PTEN loss predictor of local recurrence? Am J Surg. 195:719–725. 2008. View Article : Google Scholar : PubMed/NCBI
20	Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL and Chung YC: Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol. 37:140–147. 2011. View Article : Google Scholar : PubMed/NCBI